articleTop 1% cited
Pegylated interferon-α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data
Clinical Pharmacology & Therapeutics · 2000 · Vol. 68(5) · pp. 556–567
Abstract
Pegylated and nonpegylated interferon-alpha2b safety and pharmacodynamic profiles were comparable. Pegylated interferon-alpha2b demonstrated delayed clearance compared with nonpegylated interferon-alpha2b, consistent with once-weekly administration.
Hepatitis C virus researchSystemic Lupus Erythematosus ResearchDrug-Induced Hepatotoxicity and ProtectionPharmacokineticsMedicinePegylated interferonPharmacodynamicsInterferonPharmacologyInternal medicineAdverse effectGastroenterologyNeopterin
MeSH terms
AbsorptionInterferon alpha-2AdultAgedAntiviral AgentsChemistry, PharmaceuticalDose-Response Relationship, DrugFemaleHumansInjections, SubcutaneousMaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsRNA, Viral
Citations
506
FWCI
15.07
field-weighted impact
References
0
Percentile
99%
vs. same field & year
Citations per year
Cited by
Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C
Annals of Internal Medicine · 2004 · 2,835 citations
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
The Lancet · 2001 · 6,046 citations
Chemistry for peptide and protein PEGylation
Advanced Drug Delivery Reviews · 2002 · 1,594 citations
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
Hepatology · 2008 · 2,966 citations
Effect of pegylation on pharmaceuticals
Nature Reviews Drug Discovery · 2003 · 3,358 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.